Continuous glucose monitors are no longer just for people with diabetes. In March of last year, DexCom gained FDA clearance for its over-the-counter CGM, and then a couple of months later, its main competitor Abbott earned clearance for two over-the-counter CGM devices of its own.
The FDA cleared these over-the-counter CGMs for use in people with and without diabetes, but questions still remain about how clinicians and individuals can interpret the data that these devices collect. To explore what CGM data really means outside of diabetes care, researchers at Mass General Brigham in Boston conducted a study. The results , published this week, found that CGM readings align well with standard measures in people with diabetes but are less reliable in those without the condition.